IN8BIO INC. - COMMON STOCK

IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

16 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer

09 Dec 2021 16:30:00 By Nasdaq GlobeNewswire

IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer

16 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors

11 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update

10 Nov 2021 16:15:00 By Nasdaq GlobeNewswire

IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO

04 Nov 2021 08:00:03 By Nasdaq GlobeNewswire

IN8bio to Present at BioFuture 2021 and Advanced Therapies Congress & Expo 2021

04 Oct 2021 16:15:00 By Nasdaq GlobeNewswire

IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

10 Sep 2021 16:15:00 By Nasdaq GlobeNewswire

IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Conference

30 Aug 2021 07:00:00 By Nasdaq GlobeNewswire

IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

11 Aug 2021 08:00:01 By Nasdaq GlobeNewswire

IN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors

04 Aug 2021 08:00:01 By Nasdaq GlobeNewswire

IN8bio Announces Pricing of Initial Public Offering

30 Jul 2021 07:00:00 By Nasdaq GlobeNewswire